| abstract |
Improved nitroreductase enzymes, particularly nitroreductase enzymes for use as prodrug convertases, are provided. In particular, E. coli has improved characteristics for the activation of the prodrug CB1954 for use in gene therapy. Single and double mutants of E. coli NFSB nitroreductase are disclosed. The present invention is based on an effort to produce a nitroreductase with improved activity in the reduction of prodrugs, particularly CB1954. |